288 related articles for article (PubMed ID: 27558924)
21. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.
Yang SK; Hong M; Baek J; Choi H; Zhao W; Jung Y; Haritunians T; Ye BD; Kim KJ; Park SH; Park SK; Yang DH; Dubinsky M; Lee I; McGovern DP; Liu J; Song K
Nat Genet; 2014 Sep; 46(9):1017-20. PubMed ID: 25108385
[TBL] [Abstract][Full Text] [Related]
22. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
Makuuchi M; Kakuta Y; Umeno J; Fujii T; Takagawa T; Ibuka T; Miura M; Sasaki Y; Takahashi S; Nakase H; Kiyohara H; Tominaga K; Shimodaira Y; Hiraoka S; Ueno N; Yanai S; Yoshihara T; Kakimoto K; Matsuoka K; Hayashi R; Nanjo S; Iwama I; Ishiguro Y; Chiba H; Endo K; Kagaya T; Fukuda T; Sakata Y; Kudo T; Takagi T; Takahashi K; Naganuma M; Shinozaki M; Ogata N; Tanaka H; Narimatsu K; Miyazaki H; Ishige T; Onodera M; Hashimoto Y; Nagai H; Shimoyama Y; Naito T; Moroi R; Shiga H; ; Kinouchi Y; Andoh A; Hisamatsu T; Masamune A
J Gastroenterol; 2024 Jun; 59(6):468-482. PubMed ID: 38589597
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).
Odahara S; Uchiyama K; Kubota T; Ito Z; Takami S; Kobayashi H; Saito K; Koido S; Ohkusa T
PLoS One; 2015; 10(9):e0137798. PubMed ID: 26360046
[TBL] [Abstract][Full Text] [Related]
24. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
Broekman MMTJ; Coenen MJH; Wanten GJ; van Marrewijk CJ; Klungel OH; Verbeek ALM; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; Wong DR; de Jong DJ
Aliment Pharmacol Ther; 2017 Nov; 46(10):953-963. PubMed ID: 28914446
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y; Kinouchi Y; Shimosegawa T
J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
[TBL] [Abstract][Full Text] [Related]
27. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.
Asada A; Nishida A; Shioya M; Imaeda H; Inatomi O; Bamba S; Kito K; Sugimoto M; Andoh A
J Gastroenterol; 2016 Jan; 51(1):22-9. PubMed ID: 26590936
[TBL] [Abstract][Full Text] [Related]
28. ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease.
Jena A; Grover N; Bhatia P; Singh M; Lad D; Prasad KK; Singh H; Dutta U; Sharma V
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):25-30. PubMed ID: 36707393
[TBL] [Abstract][Full Text] [Related]
29. Influence of
Kojima Y; Hirotsu Y; Omata W; Sugimori M; Takaoka S; Ashizawa H; Nakagomi K; Yoshimura D; Hosoda K; Suzuki Y; Mochizuki H; Omata M
World J Gastroenterol; 2018 Jan; 24(4):511-518. PubMed ID: 29398872
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
Singh M; Bhaskar D; Bhatia P; Thakur R; Sharma P; Bansal D; Jain R; Trehan A
Cancer Chemother Pharmacol; 2023 Jul; 92(1):51-56. PubMed ID: 37256334
[TBL] [Abstract][Full Text] [Related]
31. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.
Dong XW; Zheng Q; Zhu MM; Tong JL; Ran ZH
World J Gastroenterol; 2010 Jul; 16(25):3187-95. PubMed ID: 20593505
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease.
Suzuki S; Uchiyama K; Motoi Y; Yoshii Y; Inoue Y; Kubota T; Odahara S; Ohtaki Y; Takami S; Ito Z; Sato N; Ohkusa T; Koido S; Saruta M
BMC Gastroenterol; 2023 Jul; 23(1):239. PubMed ID: 37454061
[TBL] [Abstract][Full Text] [Related]
34. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
Seinen ML; van Nieuw Amerongen GP; de Boer NK; Mulder CJ; van Bezu J; van Bodegraven AA
Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
[TBL] [Abstract][Full Text] [Related]
35. NUDT15 p.R139C variant is common and strongly associated with azathioprine-induced early leukopenia and severe alopecia in Korean patients with various neurological diseases.
Kim SY; Shin JH; Park JS; Kang SY; Nam TS; Kim JK; Park KJ; Huh SY; Oh JS; Kang B; Kim DS
J Neurol Sci; 2017 Jul; 378():64-68. PubMed ID: 28566182
[TBL] [Abstract][Full Text] [Related]
36. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
37. Differences in the adverse effects of azathioprine between inflammatory bowel disease and autoimmune hepatitis in Korean patients.
Lee YJ; Choi WY; Park KS; Kim YJ; Cho KB; Kim ES; Jang BK; Chung WJ; Hwang JS
Korean J Gastroenterol; 2014 Dec; 64(6):348-55. PubMed ID: 25530586
[TBL] [Abstract][Full Text] [Related]
38. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
39. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
Wilson A; Jansen LE; Rose RV; Gregor JC; Ponich T; Chande N; Khanna R; Yan B; Jairath V; Khanna N; Sey M; Beaton M; McIntosh K; Teft WA; Kim RB
Aliment Pharmacol Ther; 2018 Mar; 47(5):615-620. PubMed ID: 29270995
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
